Syncona's Blue Earth reports positive prostate study findings

7th May 2019 07:56

(Sharecast News) - Syncona on Tuesday said its portfolio company Blue Earth Diagnostics had reported positive results from a study into prostate cancer diagnosis. The study, conducted as a clinical experience in academic setting at the Technical University at Munich, used radiohybrid PSMA-targeted agent rhPSMA-7 in high-risk primary and recurrent prostate cancer.Blue Earth bought rhPSMA-7 in 2018 to extend its position in prostate cancer imaging, including potential new areas of high unmet need, such as early stage primary prostate cancer patients, Syncona said in a statement.A retrospective analysis of 58 patients with high risk primary prostate cancer indicated that 18F-rhPSMA-7 PET/CT demonstrated sensitivity of 72%, specificity of 93% and diagnostic accuracy 86%, when compared to histopathological findings."We are encouraged by these results, which provide further evidence to support the potential clinical utility of rhPSMA-7 in both high-risk primary and recurrent prostate cancer," said Sycona Investments chief executive Martin Murphy.